Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Oct 31:22:105-107.
doi: 10.1016/j.gore.2017.10.004. eCollection 2017 Nov.

Polypoid endometriosis mimicking invasive cancer in an obese, postmenopausal tamoxifen user

Affiliations
Case Reports

Polypoid endometriosis mimicking invasive cancer in an obese, postmenopausal tamoxifen user

William T Jaegle et al. Gynecol Oncol Rep. .

Abstract

Background: Tamoxifen is a medication often used for the treatment and prevention of breast cancer. It is classically associated with several gynecological side effects to include a thickened endometrial stripe, increased uterine polyp formation, and an increased risk of uterine cancer. Rarely tamoxifen use has been associated with proliferation of endometriosis often severe enough to mimic a late-stage gynecologic malignancy.

Case: A 62-year-old Gravida 0 postmenopausal female with a medical history of severe obesity, infertility, and preventative tamoxifen use presented for evaluation of gross hematuria. A CT urogram was performed and demonstrated findings concerning for carcinomatosis, likely gynecologic in origin. Cervical cancer screening was up-to-date and she had a negative colonoscopy within the prior 2 years. Serum tumor markers were remarkable only for a mildly elevated CA125 of 37.6. Diagnostic laparoscopy demonstrated apparent operable carcinomatosis limited to the pelvis. The procedure was converted to an exploratory laparotomy, where radical tumor cytoreduction was performed to no gross residual disease. Frozen sections performed intraoperatively were unclear of origin but suggestive of low malignant potential. Final pathology resulted for endometriosis.

Conclusion: This case illustrates a presentation of endometriosis in a postmenopausal woman mimicking advanced mullerian malignancy. The patient's estrogenic state from obesity in combination with the agonist action of the tamoxifen likely contributed to her rare presentation. While findings such as a thickened endometrial stripe are typical of tamoxifen use, such widespread proliferation of endometriosis resulting in a pelvic mass, genito-urinary obstruction, and plaque-like pelvic spread are not.

Précis: Endometriosis is a benign estrogen dependent condition rarely problematic in a postmenopausal patient. Tamoxifen use in the setting of an obese patient may contribute to a proliferation of pre-existing endometriosis which resembles an aggressive late-stage gynecological malignancy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
CT Urogram demonstrating intraabdominal soft tissue nodules.
Fig. 2
Fig. 2
Pelvic Ultrasound demonstrating a thickened, heterogeneous endometrial stripe.
Fig. 3
Fig. 3
Nodule of Endometriosis(left) adjacent to Ureter(right) (E&M stain).
Fig. 4
Fig. 4
CD10 Immunohistochemical stain positivity(left) on parametria.

References

    1. Bese T., Smsek Y., Bese N., Ilvan S., Arvas M. Extensive pelvic endometriosis with malignant change in tamoxifen-treated postmenopausal women. Int. J. Gynecol. Cancer. 2003 May–Jun;13(3):376–380. - PubMed
    1. Chang C., Chen P., Leu F. Florid polypoid endometriosis exacervated by tamoxifen therapy in breast cancer. Obstst. Gynecol. 2003:1127e30. - PubMed
    1. Choi I.H., Jin S., Jeen Y.M., Lee Y.M., Lee J.J., Kim D.W. Tamoxifen-associated polypoid endometriosis mimicking an ovarian neoplasm. Obstet. Gynecol. Sci. 2015;58(4):327–330. - PMC - PubMed
    1. Hajjar L.R., Kim W. Intestinal and pelvic endometriosis presenting as a tumor and associated with tamoxifen therapy: report of a case. Obstet. Gynecol. 1993;(4 pt 2 Suppl):624. - PubMed
    1. Karimi Z.M., Behtash N., Sekhavat L., Dehghan A. Effects of tamoxifen on the cervix and uterus in women with breast cancer: experience with Iranian patients and a literature review. Asian Pac. J. Cancer Prev. 2009;10(4):595–598. - PubMed

Publication types